Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Breast cancer

Roche has a long-standing commitment to transforming care in breast cancer and supporting healthcare professionals in the UK and the patients they care for.


Indications for PHESGO (pertuzumab/trastuzumab), Kadcyla (trastuzumab emtansine), Herceptin (trastuzumab), and PERJETA (pertuzumab) can be found at the end of this page.

Click for Prescribing Information and details of enhanced pregnancy prevention programme for relevant products: PHESGO, Kadcyla, Herceptin, PERJETA.
Roche has transformed the landscape for HER2+ breast cancer

From the development of Herceptin1–3 to the continued refinement of targeted therapies,4–7 Roche is dedicated to improving the lives of people living with HER2+ breast cancer. 
Go back to All videos

*EMA approvals were automatically applied to the UK prior to leaving the European Union on 31 January 2020

Addressing patient needs across settings

 

Patients with HER2+ BC need treatments to help them live, in all senses of the word.

Patient needs vary across stages of treatment; from aiming to maximise response to treatment for long-term survival in the neoadjuvant setting,12,13 to balancing effectiveness with tolerability and everyday wellbeing in the metastatic
setting.14–17

Explore information on our HER2-targeted therapies to understand how they may help address your patients’ needs.

 

Explore PHESGO and Kadcyla
Explore HER2+ BC resources
Phesgo Breast cancer
Test your treatment decision-making with case studies covering type 2 diabetes and GI event management
The breast cancer landscape is evolving, keep up to date with information from Roche

The breast cancer landscape is evolving, keep up to date with information from Roche
Register

Already have an account? Sign in

Already have an account? Sign in
Indications and prescribing information

In eBC, PHESGO is indicated for use in combination with chemotherapy in:

  • The neoadjuvant treatment of adult patients with HER2+, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence​
  • The adjuvant treatment of adult patients with HER2+ eBC at high risk of recurrence​

In mBC, PHESGO is indicated for use in combination with docetaxel for adult patients with HER2+ metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

PHESGO Prescribing Information and details of the enhanced pregnancy prevention programme

Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2+ eBC who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2+, unresectable locally advanced or mBC who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for LA or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.

Kadcyla Prescribing Information

Herceptin is indicated for the treatment of adult patients with HER2+ eBC:

  • Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)
  • Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel
  • In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin
  • In combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter


Herceptin is indicated for the treatment of adult patients with HER2+ mBC:

  • As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor-positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments
  • In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable
  • In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease
  • In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone receptor-positive mBC, not previously treated with trastuzumab

Herceptin should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.


Herceptin SC Prescribing Information

In eBC, PERJETA is indicated for use in combination with trastuzumab and chemotherapy in:

  • The neoadjuvant treatment of adult patients with HER2+, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence
  • The adjuvant treatment of adult patients with HER2+ eBC at high risk of recurrence
     

In mBC, PERJETA is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2+ metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

PERJETA Prescribing Information
Abbreviations:

1L, first line; BC, breast cancer; CDK4/6, cyclin-dependent kinase 4/6; eBC, early breast cancer; EMA; European Medicines Agency; ER, oestrogen receptor; ESMO, European Society for Medical Oncology; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; MA, marketing authorisaton; mBC, metastatic breast cancer; MHRA, Medicines and Healthcare products Regulatory Agency.
References:
  1. Eirmann W, et al. Annals of Oncology. 2001;12;S57–S62.
  2. Piccart-Gebhart MJ, et al. N Engl J Med. 2005;353:1659–1672.
  3. Romond EH, et al. N Engl J Med. 2005;353:1673–1684.
  4. Ishii K, et al. Core evidence. 2019;14:51–70.
  5. von Minckwitz G, et al. N Engl J Med. 2019;380:617–628.
  6. Tan AR, et al. Lancet Oncol. 2021;22(1):85–97.
  7. O’Shaughnessy J, et al. Eur J Cancer. 2021;152:223–32.
  8. European Medicines Agency. Herceptin. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/Herceptin. Accessed October 2026.
  9. European Medicines Agency. PERJETA. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/Perjeta. Accessed October 2026.
  10. European Medicines Agency. Kadcyla. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla. Accessed October 2026.
  11. Roche. PHESGO. Summary of Product Characteristics.
  12. Batcheleder L, et al. MDM Policy Pract. 2025;10:23814683251372622.
  13. Thill, et al. Geburtshilfe Frauenheilkd. 2016;76:551–556.
  14. Zhang M, et al. BMC Cancer. 2023;23(1):1126.
  15. Jiang S, et al. Pharmacoeconomics. 2023;41(1):43–57.
  16. Bland KA, et al. Cancers. 2023;15(17):4331.
  17. Douglas SL, et al. Curr Oncol. 2019;26(6):370–9.
  18. Roche. Kadcyla Summary of Product Characteristics.
  19. Roche. Herceptin. Summary of Product Characteristics.
  20. Roche. PERJETA Summary of Product Characteristics.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
 
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.